People walk past a CVS drug store in Manhattan, New York.
Shannon Stapleton | Reuters
CVS healthFourth-quarter earnings exceeded Wall Street expectations on Tuesday as prescription volume spiked sales and the drugstore chain attracted new customers with Covid-19 testing and vaccines.
The company’s shares fell more than 4% early Tuesday.
The company reported for the fourth fiscal quarter ended December 31, versus analyst expectations, based on an analyst survey conducted by Refinitiv:
- Earnings per share: $ 1.30 adjusted versus $ 1.24 expected
- Revenue: $ 69.55 billion versus $ 68.75 billion expected
The drugstore chain posted net income of $ 975 million, or 75 cents per share, for the fourth quarter, compared with $ 1.74 billion or $ 1.33 per share a year earlier.
Excluding items, the company earned $ 1.30 per share, beating the analysts polled by Refinitiv, which was forecasting $ 1.24 per share.
Revenue rose from $ 66.89 billion a year ago to $ 69.55 billion. That’s higher than analysts’ expectations of $ 68.75 billion.
For CVS, the pandemic has brought advantages and disadvantages. On the one hand, the global health crisis has resulted in some people skipping trips to the store and the doctor’s office. This has reduced sales in the store and has resulted in fewer new recipes. On the other hand, fewer visits to the doctor have resulted in lower costs for CVS ‘own health insurance, Aetna it was acquired in 2018. The pandemic has also given the drugstore chain an opportunity to showcase its health services like telemedicine and MinuteClinic, and to open up new business opportunities like drive-thru testing.
Sales in the same store increased by 5.3% in the three-month period compared to the same period last year. In the pharmacy division, they rose 7.5% as prescription volume increased but the front end fell 1.8% as customers had fewer visits and did not have to buy as much flu and cold medication during the pandemic.
CVS warned that the first quarter of the fiscal year will be the lowest earnings quarter of the year due to the weaker flu season and investments in the Covid vaccination program. The health care business will generate higher profits in the first half of the year, but these will taper and drop to their lowest level in the fourth quarter.
CVS predicts earnings per share for 2021 will be between $ 6.06 and $ 6.22, but after adjustments, between $ 7.39 and $ 7.55 per share. Cash flow from operating activities for the full year is projected to be between $ 12 billion and $ 12.5 billion.
Brian Tanquilut, health services research analyst at Jefferies, said the market reaction on Tuesday may reflect disappointment with the company’s outlook for the year. He expects the CVS prognosis to be conservative. He estimates the company has more than $ 700 million chance of delivering Covid vaccines.
Expansion of Covid vaccines
CVS is gradually take on a bigger role with the vaccinesbecause it gets more offer. Last week the Federal government sent cans directly to pharmacy stores – including CVS locations in 11 states.
Speaking to investors and analysts on Tuesday, CVS CEO Karen Lynch said that around 8 million consumers first came to CVS because of Covid testing. She said it expected a similar experience with vaccines.
“We will take this opportunity to create a health experience that shows the value we bring,” she said. “It will create the opportunity to expand our customer base while deepening relationships with current customers.”
She described the federal program with CVS and other pharmacies as “the linchpin of the Biden government’s plan to vaccinate 300 million Americans by the end of the summer”. She said CVS has the capacity to deliver 20 to 25 million doses per month, depending on the offer.
CVS said it ran around 15 million tests across the country. In addition, more than 3 million Covid vaccines have been administered in over 40,000 long-term care facilities.
The drugstore chain and its competitor Walgreens, signed a contract with the federal government in October to give employees and residents of nursing homes and assisted living facilities the opportunity. It started vaccinations in December and plans to deliver both doses in long-term care facilities in mid-March.
Combination of its assets
As the largest pharmacy chain in the country and a major insurance provider, CVS has pooled assets to increase sales and reduce costs. It has turned more than 650 locations into HealthHubs, where people can treat their diabetes, meet with a behavioral health therapist, or even take a yoga class. Some Aetna insurance plans encourage members to go to MinuteClinics in lieu of other health care providers by not requiring co-payment for the visits.
Lynch, the company’s new CEO, has a strong insurance background. Prior to joining the role this month, she was the head of CVS’s Aetna business. She worked for health insurance Cigna and health company Magellan Health Services before joining CVS.
Next year, the company will again participate in the public exchange created by the Affordable Care Act, which will allow people to buy their own health insurance. She said it will be CVS Health-Aetna’s first branded product. She said the exchange has stabilized and has become more attractive as a profit maker.
According to Lynch, CVS is accelerating investments in a broader range of services beyond just filling out prescriptions. She pointed out a program that brings kidney dialysis services home to reduce hospital admissions and an oncology program that matches people with clinical trials.
At the close of trading on Friday, CVS shares were up less than 1% last year. The company’s stock, valued at $ 97.13 billion, hit a 52-week high of $ 77.23 in mid-January. It closed at $ 74.21 on Friday.
Read the full press release here.